Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medivation, Inc.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
As the clock ticks down to the US election day on 3 November, President Trump maintains that the first COVID-19 vaccine emergency use approval is imminent. Meanwhile, Fujifilm Toyama's Avigan is near to Japanese approval.
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with four additional initial public offerings on 1 October.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.